Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

CAPS Rating: 5 out of 5

The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.

Recs

0
Player Avatar TyPicks (< 20) Submitted: 2/8/2007 11:02:07 AM : Outperform Start Price: $9.40 IDRA Score: -86.50

Wall Street Pro Pick.

Featured Broker Partners


Advertisement